405 results on '"inflammatory cardiomyopathy"'
Search Results
2. Mayo AVC Registry and Biobank
- Author
-
Cambridge University Hospitals NHS Foundation Trust and Virend Somers, MD, PhD, Principal Investigator
- Published
- 2024
3. New insights gained from cellular landscape changes in myocarditis and inflammatory cardiomyopathy.
- Author
-
Wang, Weiteng, Jia, Hao, Hua, Xiumeng, and Song, Jiangping
- Subjects
METABOLIC reprogramming ,RNA sequencing ,GENETIC transcription ,MYOCARDITIS - Abstract
Advances in the etiological classification of myocarditis and inflammatory cardiomyopathy (ICM) have reached a consensus. However, the mechanism of myocarditis/ICM remains unclear, which affects the development of treatment and the improvement of outcome. Cellular transcription and metabolic reprogramming, and the interactions between cardiomyocytes and non-cardiomyocytes, such as the immune cells, contribute to the process of myocarditis/ICM. Recent efforts have been made by multi-omics techniques, particularly in single-cell RNA sequencing, to gain a better understanding of the cellular landscape alteration occurring in disease during the progression. This article aims to provide a comprehensive overview of the latest studies in myocarditis/ICM, particularly as revealed by single-cell sequencing. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Diagnosis and treatment of myocarditis and inflammatory cardiomyopathy. Consensus document of the SEC-Working Group on Myocarditis.
- Author
-
Domínguez, Fernando, Uribarri, Aitor, Larrañaga-Moreira, José María, Ruiz-Guerrero, Luis, Pastor-Pueyo, Pablo, Gayán-Ordás, Jara, Fernández-González, Beatriz, Esteban-Fernández, Alberto, Barreiro, Manuel, López-Fernández, Silvia, Gutiérrez-Larraya Aguado, Federico, and Pascual-Figal, Domingo
- Abstract
Copyright of Revista Española de Cardiología (18855857) is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
5. Coordination chemistry suggests that independently observed benefits of metformin and Zn2+ against COVID-19 are not independent.
- Author
-
Lockwood, Thomas D.
- Abstract
Independent trials indicate that either oral Zn
2+ or metformin can separately improve COVID-19 outcomes by approximately 40%. Coordination chemistry predicts a mechanistic relationship and therapeutic synergy. Zn2+ deficit is a known risk factor for both COVID-19 and non-infectious inflammation. Most dietary Zn2+ is not absorbed. Metformin is a naked ligand that presumably increases intestinal Zn2+ bioavailability and active absorption by cation transporters known to transport metformin. Intracellular Zn2+ provides a natural buffer of many protease reactions; the variable "set point" is determined by Zn2+ regulation or availability. A Zn2+ -interactive protease network is suggested here. The two viral cysteine proteases are therapeutic targets against COVID-19. Viral and many host proteases are submaximally inhibited by exchangeable cell Zn2+ . Inhibition of cysteine proteases can improve COVID-19 outcomes and non-infectious inflammation. Metformin reportedly enhances the natural moderating effect of Zn2+ on bioassayed proteome degradation. Firstly, the dissociable metformin–Zn2+ complex could be actively transported by intestinal cation transporters; thereby creating artificial pathways of absorption and increased body Zn2+ content. Secondly, metformin Zn2+ coordination can create a non-natural protease inhibitor independent of cell Zn2+ content. Moderation of peptidolytic reactions by either or both mechanisms could slow (a) viral multiplication (b) viral invasion and (c) the pathogenic host inflammatory response. These combined actions could allow development of acquired immunity to clear the infection before life-threatening inflammation. Nirmatrelvir (Paxlovid®) opposes COVID-19 by selective inhibition the viral main protease by a Zn2+ -independent mechanism. Pending safety evaluation, predictable synergistic benefits of metformin and Zn2+ , and perhaps metformin/Zn2+ /Paxlovid® co-administration should be investigated. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
6. CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine (CMP-MYTHiC)
- Author
-
European Union, Ministry of Health, Italy, Mario Negri Institute for Pharmacological Research, and University of Milano Bicocca
- Published
- 2024
7. Immunosuppressive Treatment in Chronic Virus-Negative Inflammatory Cardiomyopathy (TRINITY)
- Author
-
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Technical University of Munich, Charite University, Berlin, Germany, University Hospital, Essen, University Hospital Erlangen, University Hospital Tuebingen, and Steffen Massberg, Prof. Dr. med.
- Published
- 2024
8. DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies (TORCH-Plus)
- Author
-
University Medicine Greifswald, Charite University, Berlin, Germany, German Heart Center, University of Mannheim, University Hospital Schleswig-Holstein, Medical University of Hannover, Goethe University, Universitätsklinikum Hamburg-Eppendorf, University Medical Center Mainz, University Medical Center Goettingen, Deutsches Herzzentrum Muenchen, Technical University of Munich, University Hospital Munich, Kerckhoff Klinik, and Benjamin Meder, Deputy Director - Clinic of Cardiology, Angiology and Pneumology
- Published
- 2023
9. Exploring the Role of Genetics in Sarcoidosis and Its Impact on the Development of Cardiac Sarcoidosis
- Author
-
Sanjay Sivalokanathan
- Subjects
cardiac sarcoidosis ,genetics ,sarcoid ,inflammatory cardiomyopathy ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Sarcoidosis is a multifaceted and multisystemic inflammatory disorder, the etiology of which remains unknown. However, it has been suggested that an intricate interplay between genetic, environmental, and inflammatory factors may contribute to the development and progression of sarcoidosis. Although 30–50% of patients demonstrate extra-pulmonary manifestations, cardiac involvement is rare, affecting only 2–5% of cases. Diagnosis is often challenging, relying on the careful application of clinical judgment, histopathological evidence, and imaging biomarkers. In this literature review, we aim to provide a comprehensive overview of the current understanding of the genetic basis of sarcoidosis, the contribution to the pathogenesis of the disorder, and discuss the potential link between certain genetic variants and the development of cardiac sarcoidosis.
- Published
- 2024
- Full Text
- View/download PDF
10. Exploring the Role of Genetics in Sarcoidosis and Its Impact on the Development of Cardiac Sarcoidosis.
- Author
-
Sivalokanathan, Sanjay
- Subjects
- *
SARCOIDOSIS , *LITERATURE reviews , *GENETIC variation , *JUDGMENT (Psychology) , *GENETICS , *CLINICAL medicine - Abstract
Sarcoidosis is a multifaceted and multisystemic inflammatory disorder, the etiology of which remains unknown. However, it has been suggested that an intricate interplay between genetic, environmental, and inflammatory factors may contribute to the development and progression of sarcoidosis. Although 30–50% of patients demonstrate extra-pulmonary manifestations, cardiac involvement is rare, affecting only 2–5% of cases. Diagnosis is often challenging, relying on the careful application of clinical judgment, histopathological evidence, and imaging biomarkers. In this literature review, we aim to provide a comprehensive overview of the current understanding of the genetic basis of sarcoidosis, the contribution to the pathogenesis of the disorder, and discuss the potential link between certain genetic variants and the development of cardiac sarcoidosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Sudden death of a 12-year-old boy with severe myocardial fibrosis due to inapparent chronic myocarditis.
- Author
-
Madea, B., Duval, I., and Doberentz, E.
- Abstract
Sudden death due to unknown cardiac disease in children is an unusual occurrence. An apparently healthy 12-year-old boy without any physical restrictions collapsed suddenly and died despite cardiopulmonary resuscitation. The main autopsy finding was extensive scarring of the myocardium, especially the interventricular septum. This extensive scarring was exceptional for the young age. Histologically, replacement-type fibrosis with patchy lymphomonocytic infiltrate and infiltration by macrophages were observed. The case was diagnosed as chronic myocarditis, which may have progressed to dilated cardiomyopathy with inflammation or inflammatory cardiomyopathy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Epstein-Barr Virus Lytic Transcripts Correlate with the Degree of Myocardial Inflammation in Heart Failure Patients.
- Author
-
Baumeier, Christian, Harms, Dominik, Altmann, Britta, Aleshcheva, Ganna, Wiegleb, Gordon, Bock, Thomas, Escher, Felicitas, and Schultheiss, Heinz-Peter
- Subjects
- *
EPSTEIN-Barr virus , *HEART failure patients , *T cells , *INFLAMMATION , *NUCLEOTIDE sequencing , *IMMUNOSTAINING , *GENETIC transcription - Abstract
The Epstein-Barr virus (EBV) is frequently found in endomyocardial biopsies (EMBs) from patients with heart failure, but the detection of EBV-specific DNA has not been associated with progressive hemodynamic deterioration. In this paper, we investigate the use of targeted next-generation sequencing (NGS) to detect EBV transcripts and their correlation with myocardial inflammation in EBV-positive patients with heart failure with reduced ejection fraction (HFrEF). Forty-four HFrEF patients with positive EBV DNA detection and varying degrees of myocardial inflammation were selected. EBV-specific transcripts from EMBs were enriched using a custom hybridization capture-based workflow and, subsequently, sequenced by NGS. The short-read sequencing revealed the presence of EBV-specific transcripts in 17 patients, of which 11 had only latent EBV genes and 6 presented with lytic transcription. The immunohistochemical staining for CD3+ T lymphocytes showed a significant increase in the degree of myocardial inflammation in the presence of EBV lytic transcripts, suggesting a possible influence on the clinical course. These results imply the important role of EBV lytic transcripts in the pathogenesis of inflammatory heart disease and emphasize the applicability of targeted NGS in EMB diagnostics as a basis for specific treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Coordination chemistry suggests that independently observed benefits of metformin and Zn2+ against COVID-19 are not independent
- Author
-
Lockwood, Thomas D.
- Published
- 2024
- Full Text
- View/download PDF
14. The Effects of Hydroxychloroquine in Patients With Inflammatory Cardiomyopathy (HYPIC)
- Author
-
Wuhan Central Hospital, Taihe Hospital, and Dao Wen Wang, Prof.
- Published
- 2023
15. Cardiac Sarcoidosis—Diagnostic and Therapeutic Challenges.
- Author
-
Korthals, Dennis, Bietenbeck, Michael, Könemann, Hilke, Doldi, Florian, Ventura, David, Schäfers, Michael, Mohr, Michael, Wolfes, Julian, Wegner, Felix, Yilmaz, Ali, and Eckardt, Lars
- Subjects
- *
SARCOIDOSIS , *CARDIAC magnetic resonance imaging , *POSITRON emission tomography , *CARDIAC arrest , *VENTRICULAR arrhythmia , *SYMPTOMS - Abstract
Sarcoidosis is a multisystem disorder of unknown etiology. The leading hypothesis involves an antigen-triggered dysregulated T-cell-driven immunologic response leading to non-necrotic granulomas. In cardiac sarcoidosis (CS), the inflammatory response can lead to fibrosis, culminating in clinical manifestations such as atrioventricular block and ventricular arrhythmias. Cardiac manifestations frequently present as first and isolated signs or may appear in conjunction with extracardiac manifestations. The incidence of sudden cardiac death (SCD) is high. Diagnosis remains a challenge. For a definite diagnosis, endomyocardial biopsy (EMB) is suggested. In clinical practice, compatible findings in advanced imaging using cardiovascular magnetic resonance (CMR) and/or positron emission tomography (PET) in combination with extracardiac histological proof is considered sufficient. Management revolves around the control of myocardial inflammation by employing immunosuppression. However, data regarding efficacy are merely based on observational evidence. Prevention of SCD is of particular importance and several guidelines provide recommendations regarding device therapy. In patients with manifest CS, outcome data indicate a 5-year survival of around 90% and a 10-year survival in the range of 80%. Data for patients with silent CS are conflicting; some studies suggest an overall benign course of disease while others reported contrasting observations. Future research challenges involve better understanding of the immunologic pathogenesis of the disease for a targeted therapy, improving imaging to aid early diagnosis, assessing the need for screening of asymptomatic patients and randomized trials. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Investigation into Cardiac Myhc-α 334–352-Specific TCR Transgenic Mice Reveals a Role for Cytotoxic CD4 T Cells in the Development of Cardiac Autoimmunity.
- Author
-
Sur, Meghna, Rasquinha, Mahima T., Mone, Kiruthiga, Massilamany, Chandirasegaran, Lasrado, Ninaad, Gurumurthy, Channabasavaiah, Sobel, Raymond A., and Reddy, Jay
- Subjects
- *
CYTOTOXIC T cells , *T cells , *TRANSGENIC mice , *HEART cells , *KILLER cells , *REGULATORY T cells , *T cell receptors , *KILLER cell receptors - Abstract
Myocarditis is one of the major causes of heart failure in children and young adults and can lead to dilated cardiomyopathy. Lymphocytic myocarditis could result from autoreactive CD4+ and CD8+ T cells, but defining antigen specificity in disease pathogenesis is challenging. To address this issue, we generated T cell receptor (TCR) transgenic (Tg) C57BL/6J mice specific to cardiac myosin heavy chain (Myhc)-α 334–352 and found that Myhc-α-specific TCRs were expressed in both CD4+ and CD8+ T cells. To investigate if the phenotype is more pronounced in a myocarditis-susceptible genetic background, we backcrossed with A/J mice. At the fourth generation of backcrossing, we observed that Tg T cells from naïve mice responded to Myhc-α 334–352, as evaluated by proliferation assay and carboxyfluorescein succinimidyl ester staining. The T cell responses included significant production of mainly pro-inflammatory cytokines, namely interferon (IFN)-γ, interleukin-17, and granulocyte macrophage-colony stimulating factor. While the naïve Tg mice had isolated myocardial lesions, immunization with Myhc-α 334–352 led to mild myocarditis, suggesting that further backcrossing to increase the percentage of A/J genome close to 99.99% might show a more severe disease phenotype. Further investigations led us to note that CD4+ T cells displayed the phenotype of cytotoxic T cells (CTLs) akin to those of conventional CD8+ CTLs, as determined by the expression of CD107a, IFN-γ, granzyme B natural killer cell receptor (NKG)2A, NKG2D, cytotoxic and regulatory T cell molecules, and eomesodermin. Taken together, the transgenic system described in this report may be a helpful tool to distinguish the roles of cytotoxic cardiac antigen-specific CD4+ T cells vs. those of CD8+ T cells in the pathogenesis of myocarditis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Application of magnetocardiography for myocarditis assessment in a testosterone-substituted female-to-male individual
- Author
-
Phillip Suwalski, Finn Wilke, DeLisa Fairweather, Ulf Landmesser, and Bettina Heidecker
- Subjects
Inflammatory cardiomyopathy ,Magnetocardiography ,Diagnostic method ,Therapy monitoring ,Case report ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background: The diagnosis of myocarditis remains challenging due to its diverse clinical manifestations. We recently demonstrated the ability of magnetocardiography (MCG) to screen for myocarditis and applied it successfully to detect myocarditis in this case study of a female-to-male (FtM) patient who had undergone sexual reassignment surgery. This case highlights two significant points: first, sex differences in myocarditis may be promoted by higher levels of testosterone, and second, the ability of MCG to diagnose myocarditis. Case presentation: We report on a 38-year-old FtM patient who was hospitalized for chest pain following testosterone therapy. The patient received testosterone every 2 weeks for 6 months following his FtM surgery. Two days after the last administration of testosterone, he developed chest pain. Electrocardiography identified non-significant ST elevations in V3–6, II and aVF and echocardiography revealed reduced left ventricular ejection fraction and apical hypokinesia. High-sensitivity troponin-T (539 ng/L to 676 ng/L) and creatine kinase elevation (592 U/L) were elevated. Coronary CT angiography ruled out coronary artery disease. Cardiac magnetic resonance imaging confirmed suspected myocarditis.Additionally, we used MCG to detect abnormalities in the electromagnetic field. A pathologic vector (0.179) supported the diagnosis of myocarditis in this patient. During therapy with ibuprofen the vector improved to 0.067 after 3 weeks accompanied by symptom improvement. Conclusion: Testosterone treatment may have promoted myocarditis in a FtM individual. Additional MCG assessment was consistent with a diagnosis of myocarditis and highlights the promising potential of this method to facilitate diagnostic screening for cardiomyopathy in the future.
- Published
- 2024
- Full Text
- View/download PDF
18. Inflammatory dilated cardiomyopathy associated with psoriasis: a case report
- Author
-
Hamidreza Riasi, Emad Asgari Jafarabadi, Hadis Enayati, Ali Fanoodi, Shiva Salehi, Ali-Reza Jamshidi, Forod Salehi, and Azam Rezaee
- Subjects
Psoriasis ,Inflammatory cardiomyopathy ,Heart failure ,Case report ,Medicine - Abstract
Abstract Background Psoriasis is a chronic inflammatory skin disease with a genetic basis. Psoriasis is accepted as a systemic, immune-mediated disease. Hypertension, obesity, metabolic disorders including diabetes mellitus and hyperlipidemia, and psychiatric disorders are more prevalent among children with psoriasis compared to children without psoriasis. In this study, we report a case of dramatic response of inflammatory cardiomyopathy to anti-inflammatory treatment of psoriasis; which might reveal similar pathogenesis basis of these two diseases. Case presentation A 9-year-old Caucasian boy presenting with signs and symptoms of heart failure refractory to conventional therapies was admitted to our pediatric cardiology service. As the patient also had psoriasis, and considering the fact that there might be an association between the two conditions, immunosuppressive drugs were administered, which led to a dramatic improvement in heart function. Conclusions The results of this study add to evidence linking psoriasis with inflammatory dilated cardiomyopathy. Clinicians, particularly cardiologists, must pay special attention to the cardiac complications of systemic diseases.
- Published
- 2023
- Full Text
- View/download PDF
19. State-of-the-Art of Endomyocardial Biopsy on Acute Myocarditis and Chronic Inflammatory Cardiomyopathy
- Author
-
Ammirati, Enrico, Buono, Andrea, Moroni, Francesco, Gigli, Lorenzo, Power, John R, Ciabatti, Michele, Garascia, Andrea, Adler, Eric D, and Pieroni, Maurizio
- Subjects
Cardiovascular ,Heart Disease ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,Biopsy ,Cardiac Catheterization ,Heart Failure ,Humans ,Myocarditis ,Myocardium ,Endomyocardial biopsy ,Acute myocarditis ,Inflammatory cardiomyopathy ,Viral search ,Histology ,Electroanatomic mapping ,Cardiorespiratory Medicine and Haematology ,Cardiovascular System & Hematology - Abstract
Purpose of reviewHistologic evidence of myocardial inflammatory infiltrate not secondary to an ischemic injury is required by current diagnostic criteria to reach a definite diagnosis of myocarditis. Endomyocardial biopsy (EMB) is therefore often indicated for the diagnosis of myocarditis, although it may lack sufficient sensitivity considering the limited possibility of myocardial sampling. Improving the diagnostic yield and utility of EMB is of high priority in the fields of heart failure cardiology and myocarditis in particular. The aim of the present review is to highlight indications, strengths, and shortcomings of current EMB techniques, and discuss innovations currently being tested in ongoing clinical studies, especially in the setting of acute myocarditis and chronic inflammatory cardiomyopathy.Recent findingsEMB provides unique diagnostic elements and prognostic information which can effectively guide the treatment of myocarditis. Issues affecting the diagnostic performance in the setting of acute myocarditis and chronic inflammatory cardiomyopathies will be discussed in this review in the light of recent expert consensus documents on the management of these conditions and on indication to EMB. Recent innovations using electroanatomic mapping (EAM)-guided EMB and fluoroscopic-guided EMB during temporary mechanical circulatory support have improved the utility of the procedure. EMB remains an important diagnostic test whose results need to be interpreted in the context of (1) clinical pre-test probability, (2) timing of sampling, (3) quality of sampling (4) site of sampling, (5) histologic type of myocarditis, and (6) analytic methods that are applied. Herein we will review these caveats as well as perspectives and innovations related to the use of this diagnostic tool.
- Published
- 2022
20. Myocarditis and Chronic Inflammatory Cardiomyopathy, from Acute Inflammation to Chronic Inflammatory Damage: An Update on Pathophysiology and Diagnosis.
- Author
-
Uccello, Giuseppe, Bonacchi, Giacomo, Rossi, Valentina Alice, Montrasio, Giulia, and Beltrami, Matteo
- Subjects
- *
MYOCARDITIS , *CARDIOMYOPATHIES , *PATHOLOGICAL physiology , *DIAGNOSIS , *HEART failure , *CARDIAC magnetic resonance imaging - Abstract
Acute myocarditis covers a wide spectrum of clinical presentations, from uncomplicated myocarditis to severe forms complicated by hemodynamic instability and ventricular arrhythmias; however, all these forms are characterized by acute myocardial inflammation. The term "chronic inflammatory cardiomyopathy" describes a persistent/chronic inflammatory condition with a clinical phenotype of dilated and/or hypokinetic cardiomyopathy associated with symptoms of heart failure and increased risk for arrhythmias. A continuum can be identified between these two conditions. The importance of early diagnosis has grown markedly in the contemporary era with various diagnostic tools available. While cardiac magnetic resonance (CMR) is valid for diagnosis and follow-up, endomyocardial biopsy (EMB) should be considered as a first-line diagnostic modality in all unexplained acute cardiomyopathies complicated by hemodynamic instability and ventricular arrhythmias, considering the local expertise. Genetic counseling should be recommended in those cases where a genotype–phenotype association is suspected, as this has significant implications for patients' and their family members' prognoses. Recognition of the pathophysiological pathway and clinical "red flags" and an early diagnosis may help us understand mechanisms of progression, tailor long-term preventive and therapeutic strategies for this complex disease, and ultimately improve clinical outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. New-onset heart failure in infants: when the aetiological diagnosis becomes a challenge.
- Author
-
Esmel-Vilomara, Roger, Riaza, Lucía, Dolader, Paola, Sabaté-Rotés, Anna, Rosés-Noguer, Ferran, and Gran, Ferran
- Subjects
- *
HEART failure , *CARDIAC magnetic resonance imaging , *HEART diseases , *INFANTS , *DILATED cardiomyopathy , *CHILD patients - Abstract
This study aimed to report the findings of cardiac magnetic resonance imaging (CMR) with quantitative mappings in infants presenting with new-onset heart failure, as well as to assess the capabilities of endomyocardial biopsy (EMB) and CMR in detecting inflammatory cardiomyopathies and determining their etiology. In a prospective analysis of infants who underwent CMR with tissue mappings, EMB, and genetic testing, the sample was categorized into two groups: those with inflammatory cardiomyopathy and negative genetics (indicative of possible myocarditis) and those with positive genetics (indicative of possible dilated cardiomyopathy). All patients exhibited similar clinical presentations, echocardiographic dysfunction, and elevated troponins and NT-proBNP levels. Additionally, they all met the diagnostic criteria for inflammatory cardiomyopathy based on EMB findings (≥14 mononuclear cells, ≥7 T-lymphocytes/mm2). EMB results unveiled significant differences in the presence of inflammation and edema between the two groups, with higher troponin levels correlating with increased inflammation. Notably, when focusing on CMR, neither the classic criteria nor the 2018 Lake Louise criteria (LLC) could effectively differentiate between the two groups. Only late gadolinium enhancement (LGE) appeared to be associated with myocarditis in this cohort, while other LLC and tissue mappings did not exhibit a similar correlation. Importantly, there was no observed correlation between the inflammation detected through EMB and CMR. Conclusions: The onset of heart dysfunction in infants can result from either inherited factors or viral infections, both of which may involve inflammation. However, the precise role of EMB and CMR in determining the etiology of such cases remains poorly defined. While CMR demonstrates high sensitivity in detecting inflammation, our experience suggests that it may not effectively differentiate between these two groups. A comprehensive diagnostic approach is essential when addressing this challenge, which includes considering EMB (with attention to the number of T-lymphocytes and the presence of oedema), specific CMR criteria, notably LGE and tissue mappings, as well as the identification of viral agents in cardiac tissue and troponin levels. Additionally, genetic tests should be conducted when evaluating these patients. What is Known: • EMB is the gold standard diagnostic test for myocarditis but it is not universally accepted. • The diagnostic value of the 2018-LLC in pediatric patients is still undefined. What is New: • Both EMB and CMR may show inflammation in infants with new-onset heart failure of any aetiology. • A global approach should be used when facing this diagnostic challenge, including the EMB (number of T-lymphocytes and oedema), some CMR criteria, specially LGE and mappings, the detection of viral agents in cardiac tissue and troponins. Genetic tests should also be performed when studying these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Inflammatory dilated cardiomyopathy associated with psoriasis: a case report.
- Author
-
Riasi, Hamidreza, Asgari Jafarabadi, Emad, Enayati, Hadis, Fanoodi, Ali, Salehi, Shiva, Jamshidi, Ali-Reza, Salehi, Forod, and Rezaee, Azam
- Subjects
- *
DILATED cardiomyopathy , *PSORIASIS , *MENTAL illness , *SKIN diseases , *SYMPTOMS , *HEART failure - Abstract
Background: Psoriasis is a chronic inflammatory skin disease with a genetic basis. Psoriasis is accepted as a systemic, immune-mediated disease. Hypertension, obesity, metabolic disorders including diabetes mellitus and hyperlipidemia, and psychiatric disorders are more prevalent among children with psoriasis compared to children without psoriasis. In this study, we report a case of dramatic response of inflammatory cardiomyopathy to anti-inflammatory treatment of psoriasis; which might reveal similar pathogenesis basis of these two diseases. Case presentation: A 9-year-old Caucasian boy presenting with signs and symptoms of heart failure refractory to conventional therapies was admitted to our pediatric cardiology service. As the patient also had psoriasis, and considering the fact that there might be an association between the two conditions, immunosuppressive drugs were administered, which led to a dramatic improvement in heart function. Conclusions: The results of this study add to evidence linking psoriasis with inflammatory dilated cardiomyopathy. Clinicians, particularly cardiologists, must pay special attention to the cardiac complications of systemic diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. The inflammatory spectrum of cardiomyopathies
- Author
-
Nicolas Musigk, Phillip Suwalski, Ainoosh Golpour, DeLisa Fairweather, Karin Klingel, Pilar Martin, Andrea Frustaci, Leslie T. Cooper, Thomas F. Lüscher, Ulf Landmesser, and Bettina Heidecker
- Subjects
myocarditis ,inflammatory cardiomyopathy ,heart failure ,cardiomyopathy ,endomyocardial biopsy (EMB) ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Infiltration of the myocardium with various cell types, cytokines and chemokines plays a crucial role in the pathogenesis of cardiomyopathies including inflammatory cardiomyopathies and myocarditis. A more comprehensive understanding of the precise immune mechanisms involved in acute and chronic myocarditis is essential to develop novel therapeutic approaches. This review offers a comprehensive overview of the current knowledge of the immune landscape in cardiomyopathies based on etiology. It identifies gaps in our knowledge about cardiac inflammation and emphasizes the need for new translational approaches to improve our understanding thus enabling development of novel early detection methods and more effective treatments.
- Published
- 2024
- Full Text
- View/download PDF
24. Epstein-Barr Virus Lytic Transcripts Correlate with the Degree of Myocardial Inflammation in Heart Failure Patients
- Author
-
Christian Baumeier, Dominik Harms, Britta Altmann, Ganna Aleshcheva, Gordon Wiegleb, Thomas Bock, Felicitas Escher, and Heinz-Peter Schultheiss
- Subjects
endomyocardial biopsy ,heart failure ,myocarditis ,inflammatory cardiomyopathy ,Epstein-Barr virus ,next-generation sequencing ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
The Epstein-Barr virus (EBV) is frequently found in endomyocardial biopsies (EMBs) from patients with heart failure, but the detection of EBV-specific DNA has not been associated with progressive hemodynamic deterioration. In this paper, we investigate the use of targeted next-generation sequencing (NGS) to detect EBV transcripts and their correlation with myocardial inflammation in EBV-positive patients with heart failure with reduced ejection fraction (HFrEF). Forty-four HFrEF patients with positive EBV DNA detection and varying degrees of myocardial inflammation were selected. EBV-specific transcripts from EMBs were enriched using a custom hybridization capture-based workflow and, subsequently, sequenced by NGS. The short-read sequencing revealed the presence of EBV-specific transcripts in 17 patients, of which 11 had only latent EBV genes and 6 presented with lytic transcription. The immunohistochemical staining for CD3+ T lymphocytes showed a significant increase in the degree of myocardial inflammation in the presence of EBV lytic transcripts, suggesting a possible influence on the clinical course. These results imply the important role of EBV lytic transcripts in the pathogenesis of inflammatory heart disease and emphasize the applicability of targeted NGS in EMB diagnostics as a basis for specific treatment.
- Published
- 2024
- Full Text
- View/download PDF
25. Transgenic Mice Expressing Functional TCRs Specific to Cardiac Myhc-α 334–352 on Both CD4 and CD8 T Cells Are Resistant to the Development of Myocarditis on C57BL/6 Genetic Background.
- Author
-
Sur, Meghna, Rasquinha, Mahima T., Arumugam, Rajkumar, Massilamany, Chandirasegaran, Gangaplara, Arunkumar, Mone, Kiruthiga, Lasrado, Ninaad, Yalaka, Bharathi, Doiphode, Aakash, Gurumurthy, Channabasavaiah, Steffen, David, and Reddy, Jay
- Subjects
- *
TRANSGENIC mice , *T cells , *CD8 antigen , *T cell receptors , *MYOCARDITIS , *SUDDEN death , *CD4 antigen , *DILATED cardiomyopathy - Abstract
Myocarditis is a predominant cause of congestive heart failure and sudden death in children and young adolescents that can lead to dilated cardiomyopathy. Lymphocytic myocarditis mediated by T cells can result from the recognition of cardiac antigens that may involve CD4 or CD8 T cells or both. In this report, we describe the generation of T cell receptor (TCR) transgenic mice on a C57BL/6 genetic background specific to cardiac myosin heavy chain (Myhc)-α 334–352 and make the following observations: First, we verified that Myhc-α 334–352 was immunogenic in wild-type C57BL/6 mice and induced antigen-specific CD4 T cell responses despite being a poor binder of IAb; however, the immunized animals developed only mild myocarditis. Second, TCRs specific to Myhc-α 334–352 in transgenic mice were expressed in both CD4 and CD8 T cells, suggesting that the expression of epitope-specific TCR is common to both cell types. Third, although T cells from naïve transgenic mice did not respond to Myhc-α 334–352, both CD4 and CD8 T cells from animals immunized with Myhc-α 334–352 responded to the peptide, indicating that antigen priming is necessary to break tolerance. Fourth, although the transgenic T cells could produce significant amounts of interferon-γ and interleukin-17, the immunized animals developed only mild disease, indicating that other soluble factors might be necessary for developing severe myocarditis. Alternatively, the C57BL/6 genetic background might be a major contributing factor for resistance to the development of myocarditis. Taken together, our model permits the determination of the roles of both CD4 and CD8 T cells to understand the disease-resistance mechanisms of myocarditis in a single transgenic system antigen-specifically. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
26. Advancing Precision Medicine in Myocarditis: Current Status and Future Perspectives in Endomyocardial Biopsy-Based Diagnostics and Therapeutic Approaches.
- Author
-
Baumeier, Christian, Harms, Dominik, Aleshcheva, Ganna, Gross, Ulrich, Escher, Felicitas, and Schultheiss, Heinz-Peter
- Subjects
- *
MYOCARDITIS , *INDIVIDUALIZED medicine , *GENE expression , *GENE expression profiling , *CARDIOMYOPATHIES , *VIRAL encephalitis - Abstract
The diagnosis and specific and causal treatment of myocarditis and inflammatory cardiomyopathy remain a major clinical challenge. Despite the rapid development of new imaging techniques, endomyocardial biopsies remain the gold standard for accurate diagnosis of inflammatory myocardial disease. With the introduction and continued development of immunohistochemical inflammation diagnostics in combination with viral nucleic acid testing, myocarditis diagnostics have improved significantly since their introduction. Together with new technologies such as miRNA and gene expression profiling, quantification of specific immune cell markers, and determination of viral activity, diagnostic accuracy and patient prognosis will continue to improve in the future. In this review, we summarize the current knowledge on the pathogenesis and diagnosis of myocarditis and inflammatory cardiomyopathies and highlight future perspectives for more in-depth and specialized biopsy diagnostics and precision, personalized medicine approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
27. Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document.
- Author
-
Ammirati, Enrico, Frigerio, Maria, Adler, Eric, Basso, Cristina, Birnie, David, Brambatti, Michela, Friedrich, Matthias, Klingel, Karin, Lehtonen, Jukka, Moslehi, Javid, Pedrotti, Patrizia, Rimoldi, Ornella, Schultheiss, Heinz-Peter, Tschöpe, Carsten, Cooper, Leslie, and Camici, Paolo
- Subjects
cardiac magnetic resonance imaging ,endomyocardial biopsy ,inflammatory cardiomyopathy ,myocarditis ,viruses ,Acute Disease ,Cardiology ,Chronic Disease ,Consensus ,Humans ,Myocarditis ,Predictive Value of Tests ,Risk Factors ,Terminology as Topic ,Treatment Outcome - Abstract
Myocarditis is an inflammatory disease of the heart that may occur because of infections, immune system activation, or exposure to drugs. The diagnosis of myocarditis has changed due to the introduction of cardiac magnetic resonance imaging. We present an expert consensus document aimed to summarize the common terminology related to myocarditis meanwhile highlighting some areas of controversies and uncertainties and the unmet clinical needs. In fact, controversies persist regarding mechanisms that determine the transition from the initial trigger to myocardial inflammation and from acute myocardial damage to chronic ventricular dysfunction. It is still uncertain which viruses (besides enteroviruses) cause direct tissue damage, act as triggers for immune-mediated damage, or both. Regarding terminology, myocarditis can be characterized according to etiology, phase, and severity of the disease, predominant symptoms, and pathological findings. Clinically, acute myocarditis (AM) implies a short time elapsed from the onset of symptoms and diagnosis (generally
- Published
- 2020
28. Cardiac Sarcoidosis—Diagnostic and Therapeutic Challenges
- Author
-
Dennis Korthals, Michael Bietenbeck, Hilke Könemann, Florian Doldi, David Ventura, Michael Schäfers, Michael Mohr, Julian Wolfes, Felix Wegner, Ali Yilmaz, and Lars Eckardt
- Subjects
cardiac sarcoidosis ,inflammatory cardiomyopathy ,ventricular arrhythmia ,sudden cardiac death ,implantable cardioverter–defibrillator ,cardiovascular magnetic resonance ,Medicine - Abstract
Sarcoidosis is a multisystem disorder of unknown etiology. The leading hypothesis involves an antigen-triggered dysregulated T-cell-driven immunologic response leading to non-necrotic granulomas. In cardiac sarcoidosis (CS), the inflammatory response can lead to fibrosis, culminating in clinical manifestations such as atrioventricular block and ventricular arrhythmias. Cardiac manifestations frequently present as first and isolated signs or may appear in conjunction with extracardiac manifestations. The incidence of sudden cardiac death (SCD) is high. Diagnosis remains a challenge. For a definite diagnosis, endomyocardial biopsy (EMB) is suggested. In clinical practice, compatible findings in advanced imaging using cardiovascular magnetic resonance (CMR) and/or positron emission tomography (PET) in combination with extracardiac histological proof is considered sufficient. Management revolves around the control of myocardial inflammation by employing immunosuppression. However, data regarding efficacy are merely based on observational evidence. Prevention of SCD is of particular importance and several guidelines provide recommendations regarding device therapy. In patients with manifest CS, outcome data indicate a 5-year survival of around 90% and a 10-year survival in the range of 80%. Data for patients with silent CS are conflicting; some studies suggest an overall benign course of disease while others reported contrasting observations. Future research challenges involve better understanding of the immunologic pathogenesis of the disease for a targeted therapy, improving imaging to aid early diagnosis, assessing the need for screening of asymptomatic patients and randomized trials.
- Published
- 2024
- Full Text
- View/download PDF
29. Case report: Recurrence of inflammatory cardiomyopathy detected by magnetocardiography
- Author
-
Phillip Suwalski, Ainoosh Golpour, Nicolas Musigk, Finn Wilke, Ulf Landmesser, and Bettina Heidecker
- Subjects
inflammatory cardiomyopathy ,magnetocardiography ,diagnostic method ,therapy monitoring ,case report ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
BackgroundThe diagnosis of inflammatory cardiomyopathies remains challenging. Life-threatening conditions such as acute coronary syndrome (ACS) always have to be considered as differential diagnoses due to similarities in presentation. Diagnostic methods for inflammatory cardiomyopathy include endomyocardial biopsy (EMB), cardiac magnetic resonance imaging (CMR), and positron emission tomography-computed tomography (PET-CT). We report a case in whom magnetocardiography (MCG) led to an initial diagnosis of inflammatory cardiomyopathy and in whom MCG was used for subsequent monitoring of treatment response under immunosuppression.Case presentationA 53-year-old man presented with two recurrent episodes of inflammatory cardiomyopathy within a 2-year period. The patient initially presented with reduced exercise capacity. Echocardiography revealed a moderately reduced left ventricular ejection fraction (LVEF 40%). Coronary angiography ruled out obstructive coronary artery disease (CAD) and an EMB was performed. The EMB revealed inflammatory cardiomyopathy without viral pathogens or replication. Moreover, we performed MCG, which confirmed a pathological Tbeg-Tmax vector of 0.108. We recently established a cutoff value of Tbeg-Tmax of 0.051 or greater for the diagnosis of inflammatory cardiomyopathy. Immunosuppressive therapy with prednisolone was initiated, resulting in clinical improvement and an LVEF increase from 40% to 45% within 1 month. Furthermore, the MCG vector improved to 0.036, which is considered normal based on our previous findings. The patient remained clinically stable for 23 months. During a routine follow-up, MCG revealed an abnormal Tbeg-Tmax vector of 0.069. The patient underwent additional testing including routine laboratory values, echocardiography (LVEF 35%), and PET-CT. PET-CT revealed increased metabolism in the myocardium—primarily in the lateral wall. Therapy with prednisolone and azathioprine was initiated and MCG was used to monitor the effect of immunosuppressive therapy.ConclusionIn addition to diagnostic screening, MCG has the potential to become a valuable method for surveillance monitoring of patients who have completed treatment for inflammatory cardiomyopathy. Furthermore, it could be used for treatment monitoring. While changes in the magnetic vector of the heart are not specific to inflammatory cardiomyopathy, as they may also occur in other types of cardiomyopathies, MCG offers a tool of broad and efficient diagnostic screening for cardiac pathologies without side effects.
- Published
- 2023
- Full Text
- View/download PDF
30. Morphological Changes in the Myocardium of Patients with Post-Acute Coronavirus Syndrome: A Study of Endomyocardial Biopsies.
- Author
-
Makarov, Igor, Mayrina, Sofya, Makarova, Taiana, Karonova, Tatiana, Starshinova, Anna, Kudlay, Dmitry, and Mitrofanova, Lubov
- Subjects
- *
POST-acute COVID-19 syndrome , *CORONAVIRUS diseases , *CORONAVIRUSES , *MYOCARDIUM , *PYTHON programming language , *COVID-19 - Abstract
The clinical manifestation study of post-acute sequelae of SARS-CoV-2 infection (PASC) has shown a lack of knowledge regarding its morphology and pathogenesis. The aim of this research was to investigate morphological manifestations of PASC in the myocardium. Materials and Methods: The study included 38 patients requiring endomyocardial biopsy (EMB) during the post-acute phase of coronavirus infection and a control group including patients requiring EMB prior to the SARS-CoV-2 pandemic. The patients' clinical and laboratory data were analyzed. Histological examination and immunohistochemistry (IHC) of the myocardial tissue was conducted with antibodies to CD3, CD68, HLA-DR, MHC1, C1q, VP1 enteroviruses, spike protein SARS-CoV-2, Ang1, von Willebrand factor (VWF), and VEGF. The morphometric analysis included counting the mean number of inflammatory infiltrate cells per mm2 and evaluating the expression of SARS-CoV-2 spike protein, HLA-DR, MHC1, C1q, Ang1, VWF, and VEGF using a scoring system. If the expression of SARS-CoV-2 spike protein was >3 points, an additional IHC test with antibodies to ACE2, CD16 as well as RT-PCR testing of the myocardial tissue were performed. For two patients, immunofluorescence tests of the myocardial tissue were performed using antibody cocktails to SARS-CoV-2 spike protein/CD16, SARS-CoV-2 spike protein/CD68, CD80/CD163. The statistical data analysis was carried out using the Python programming language and libraries such as NumPy, SciPy, Pandas, and Matplotlib. Results: The study demonstrated a significant increase in the number of CD68+ macrophages in the myocardium of PASC patients compared to patients who did not have a history of COVID-19 (p = 0.014 and p = 0.007 for patients with and without myocarditis, respectively), predominantly due to M2 macrophages. An increase in the number of CD68+ macrophages was more frequently observed in patients with shorter intervals between the most recent positive SARS-CoV-2 PCR test and the time of performing the EMB (r = −0.33 and r = −0.61 for patients with and without myocarditis, respectively). The expression scores of Ang1, VEGF, VWF, and C1q in PASC patients did not significantly differ from those in EMB samples taken before 2019. Conclusion: The myocardium of PASC patients demonstrated a significant increase in the number of CD68+ macrophages and a decrease in the expression of markers associated with angiopathy. No evidence of coronavirus-associated myocarditis was observed in any PASC patient. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
31. Myocarditis: Etiology, Pathogenesis, and Their Implications in Clinical Practice.
- Author
-
Brociek, Emil, Tymińska, Agata, Giordani, Andrea Silvio, Caforio, Alida Linda Patrizia, Wojnicz, Romuald, Grabowski, Marcin, and Ozierański, Krzysztof
- Subjects
- *
MYOCARDITIS , *CARDIOMYOPATHIES , *DILATED cardiomyopathy , *CARDIAC arrest , *ETIOLOGY of diseases - Abstract
Simple Summary: Myocarditis is an inflammatory disease of the myocardium which can lead to serious short-term and long-term sequalae such as sudden cardiac death or dilated cardiomyopathy. It is caused by infectious and non-infectious factors; however, our understanding of processes that govern its pathogenesis is limited. The aim of this review is to summarize available evidence regarding the etiology and pathogenesis of myocarditis, as well as to outline the impact that they have on disease course and patient management. Myocarditis is an inflammatory disease of the myocardium caused by infectious or non-infectious agents. It can lead to serious short-term and long-term sequalae, such as sudden cardiac death or dilated cardiomyopathy. Due to its heterogenous clinical presentation and disease course, challenging diagnosis and limited evidence for prognostic stratification, myocarditis poses a great challenge to clinicians. As it stands, the pathogenesis and etiology of myocarditis is only partially understood. Moreover, the impact of certain clinical features on risk assessment, patient outcomes and treatment options is not entirely clear. Such data, however, are essential in order to personalize patient care and implement novel therapeutic strategies. In this review, we discuss the possible etiologies of myocarditis, outline the key processes governing its pathogenesis and summarize best available evidence regarding patient outcomes and state-of-the-art therapeutic approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
32. Giant Cell Myocarditis
- Author
-
Vaideeswar, Pradeep, Ingle, Ketan, and Vaideeswar, Pradeep, editor
- Published
- 2022
- Full Text
- View/download PDF
33. Acute Lymphocytic Myocarditis and Sudden Cardiac Death
- Author
-
Ingle, Ketan, Tasgaonkar, Girish, Vaideeswar, Pradeep, and Vaideeswar, Pradeep, editor
- Published
- 2022
- Full Text
- View/download PDF
34. Immunosuppressive Therapy of Biopsy-Proven, Virus-Negative, Autoimmune/Immune-Mediated Myocarditis—Focus on Azathioprine: A Review of Existing Evidence and Future Perspectives.
- Author
-
Grzechocińska, Justyna, Tymińska, Agata, Giordani, Andrea Silvio, Wysińska, Julia, Ostrowska, Ewa, Baritussio, Anna, Caforio, Alida Linda Patrizia, Grabowski, Marcin, Marcolongo, Renzo, and Ozierański, Krzysztof
- Subjects
- *
AZATHIOPRINE , *MYOCARDITIS , *IMMUNOSUPPRESSIVE agents , *ARRHYTHMIA , *CARDIAC arrest , *DILATED cardiomyopathy , *HEART failure - Abstract
Simple Summary: Myocarditis is one of the leading causes of acute and chronic heart failure, adverse ventricular remodelling, and progression to dilated cardiomyopathy, life-threatening arrhythmias, and sudden cardiac death. According to recent guidelines, azathioprine, in association with steroids, is a cornerstone of first-line therapy regimens in biopsy-proven, autoimmune/immune-mediated, virus-negative myocarditis. Despite that the majority of published clinical studies seem to show an overall benefit of immunosuppressive therapy in the treatment of myocarditis/inflammatory cardiomyopathy, a targeted therapy has still not been standardized, and there is a need for further controlled, multicentric, clinical studies to provide further data on the efficacy and safety of IT in myocarditis. The aim of this review is to describe the pharmacological properties of azathioprine and to explore future perspectives for its usage in the cardioimmunology field. The use of immunosuppressive therapy (IT) in biopsy-proven, autoimmune/immune-mediated (AI), virus-negative myocarditis has become the standard of care. In particular, according to recent guidelines, azathioprine (AZA), in association with steroids, is a cornerstone of first-line therapy regimens. IT may have a crucial impact on the natural history of AI myocarditis, preventing its progression to end-stage heart failure, cardiovascular death, or heart transplantation, provided that strict appropriateness and safety criteria are observed. In particular, AZA treatment for AI virus-negative myocarditis requires the consideration of some crucial aspects regarding its pharmacokinetics and pharmacodynamics, as well as a high index of suspicion to detect its overt and/or subclinical side effects. Importantly, besides a tight teamwork with a clinical immunologist/immuno-rheumatologist, before starting IT, it is also necessary to carry out a careful "safety check-list" in order to rule out possible contraindications to IT and minimize patient's risk. The aim of this review is to describe the pharmacological properties of AZA, as well as to discuss practical aspects of its clinical use, in the light of existing evidence, with particular regard to the new field of cardioimmunology. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
35. Exploring potential biomarkers and therapeutic targets of long COVID-associated inflammatory cardiomyopathy
- Author
-
Peng Qi, Mengjie Huang, and Haiyan Zhu
- Subjects
COVID-19 ,long COVID ,inflammatory cardiomyopathy ,bioinformatic analysis ,differentially expressed genes ,Medicine (General) ,R5-920 - Abstract
BackgroundThe negative impact of long COVID on social life and human health is increasingly prominent, and the elevated risk of cardiovascular disease in patients recovering from COVID-19 has also been fully confirmed. However, the pathogenesis of long COVID-related inflammatory cardiomyopathy is still unclear. Here, we explore potential biomarkers and therapeutic targets of long COVID-associated inflammatory cardiomyopathy.MethodsDatasets that met the study requirements were identified in Gene Expression Omnibus (GEO), and differentially expressed genes (DEGs) were obtained by the algorithm. Then, functional enrichment analysis was performed to explore the basic molecular mechanisms and biological processes associated with DEGs. A protein–protein interaction (PPI) network was constructed and analyzed to identify hub genes among the common DEGs. Finally, a third dataset was introduced for validation.ResultsUltimately, 3,098 upregulated DEGs and 1965 downregulated DEGs were extracted from the inflammatory cardiomyopathy dataset. A total of 89 upregulated DEGs and 217 downregulated DEGs were extracted from the dataset of convalescent COVID patients. Enrichment analysis and construction of the PPI network confirmed VEGFA, FOXO1, CXCR4, and SMAD4 as upregulated hub genes and KRAS and TXN as downregulated hub genes. The separate dataset of patients with COVID-19 infection used for verification led to speculation that long COVID-associated inflammatory cardiomyopathy is mainly attributable to the immune-mediated response and inflammation rather than to direct infection of cells by the virus.ConclusionScreening of potential biomarkers and therapeutic targets sheds new light on the pathogenesis of long COVID-associated inflammatory cardiomyopathy as well as potential therapeutic approaches. Further clinical studies are needed to explore these possibilities in light of the increasingly severe negative impacts of long COVID.
- Published
- 2023
- Full Text
- View/download PDF
36. Investigation into Cardiac Myhc-α 334–352-Specific TCR Transgenic Mice Reveals a Role for Cytotoxic CD4 T Cells in the Development of Cardiac Autoimmunity
- Author
-
Meghna Sur, Mahima T. Rasquinha, Kiruthiga Mone, Chandirasegaran Massilamany, Ninaad Lasrado, Channabasavaiah Gurumurthy, Raymond A. Sobel, and Jay Reddy
- Subjects
TCR transgenic mice ,cardiac myosin-α 334–352 ,myocarditis ,inflammatory cardiomyopathy ,Cytology ,QH573-671 - Abstract
Myocarditis is one of the major causes of heart failure in children and young adults and can lead to dilated cardiomyopathy. Lymphocytic myocarditis could result from autoreactive CD4+ and CD8+ T cells, but defining antigen specificity in disease pathogenesis is challenging. To address this issue, we generated T cell receptor (TCR) transgenic (Tg) C57BL/6J mice specific to cardiac myosin heavy chain (Myhc)-α 334–352 and found that Myhc-α-specific TCRs were expressed in both CD4+ and CD8+ T cells. To investigate if the phenotype is more pronounced in a myocarditis-susceptible genetic background, we backcrossed with A/J mice. At the fourth generation of backcrossing, we observed that Tg T cells from naïve mice responded to Myhc-α 334–352, as evaluated by proliferation assay and carboxyfluorescein succinimidyl ester staining. The T cell responses included significant production of mainly pro-inflammatory cytokines, namely interferon (IFN)-γ, interleukin-17, and granulocyte macrophage-colony stimulating factor. While the naïve Tg mice had isolated myocardial lesions, immunization with Myhc-α 334–352 led to mild myocarditis, suggesting that further backcrossing to increase the percentage of A/J genome close to 99.99% might show a more severe disease phenotype. Further investigations led us to note that CD4+ T cells displayed the phenotype of cytotoxic T cells (CTLs) akin to those of conventional CD8+ CTLs, as determined by the expression of CD107a, IFN-γ, granzyme B natural killer cell receptor (NKG)2A, NKG2D, cytotoxic and regulatory T cell molecules, and eomesodermin. Taken together, the transgenic system described in this report may be a helpful tool to distinguish the roles of cytotoxic cardiac antigen-specific CD4+ T cells vs. those of CD8+ T cells in the pathogenesis of myocarditis.
- Published
- 2024
- Full Text
- View/download PDF
37. Myocarditis and Chronic Inflammatory Cardiomyopathy, from Acute Inflammation to Chronic Inflammatory Damage: An Update on Pathophysiology and Diagnosis
- Author
-
Giuseppe Uccello, Giacomo Bonacchi, Valentina Alice Rossi, Giulia Montrasio, and Matteo Beltrami
- Subjects
inflammatory cardiomyopathy ,myocarditis ,sarcoidosis ,systemic sclerosis ,systemic lupus erythematosus ,eosinophilic granulomatosis with polyangiitis ,Medicine - Abstract
Acute myocarditis covers a wide spectrum of clinical presentations, from uncomplicated myocarditis to severe forms complicated by hemodynamic instability and ventricular arrhythmias; however, all these forms are characterized by acute myocardial inflammation. The term “chronic inflammatory cardiomyopathy” describes a persistent/chronic inflammatory condition with a clinical phenotype of dilated and/or hypokinetic cardiomyopathy associated with symptoms of heart failure and increased risk for arrhythmias. A continuum can be identified between these two conditions. The importance of early diagnosis has grown markedly in the contemporary era with various diagnostic tools available. While cardiac magnetic resonance (CMR) is valid for diagnosis and follow-up, endomyocardial biopsy (EMB) should be considered as a first-line diagnostic modality in all unexplained acute cardiomyopathies complicated by hemodynamic instability and ventricular arrhythmias, considering the local expertise. Genetic counseling should be recommended in those cases where a genotype–phenotype association is suspected, as this has significant implications for patients’ and their family members’ prognoses. Recognition of the pathophysiological pathway and clinical “red flags” and an early diagnosis may help us understand mechanisms of progression, tailor long-term preventive and therapeutic strategies for this complex disease, and ultimately improve clinical outcomes.
- Published
- 2023
- Full Text
- View/download PDF
38. Role of Endomyocardial Biopsy and Aetiology-based Treatment in Patients With Inflammatory Heart Disease in Arrhythmic and Non-arrhythmic Clinical Presentations: an Integrated Approach for the Optimal Diagnostic and Therapeutic Management (MYOCAR)
- Author
-
Giovanni Peretto, MD, Principal Investigator
- Published
- 2020
39. Application of Magnetocardiography to Screen for Inflammatory Cardiomyopathy and Monitor Treatment Response
- Author
-
Debora Brala, Tharusan Thevathasan, Simon Grahl, Steve Barrow, Michele Violano, Hendrikje Bergs, Ainoosh Golpour, Phillip Suwalski, Wolfgang Poller, Carsten Skurk, Ulf Landmesser, and Bettina Heidecker
- Subjects
COVID‐19 ,echocardiography ,ejection fraction ,immunosuppressive therapy ,inflammatory cardiomyopathy ,magnetocardiography ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background Inflammatory cardiomyopathy is one of the most common causes of sudden cardiac death in young adults. Diagnosis of inflammatory cardiomyopathy remains challenging, and better monitoring tools are needed. We present magnetocardiography as a method to diagnose myocardial inflammation and monitor treatment response. Methods and Results A total of 233 patients were enrolled, with a mean age of 45 (±18) years, and 105 (45%) were women. The primary analysis included 209 adult subjects, of whom 66 (32%) were diagnosed with inflammatory cardiomyopathy, 17 (8%) were diagnosed with cardiac amyloidosis, and 35 (17%) were diagnosed with other types of nonischemic cardiomyopathy; 91 (44%) did not have cardiomyopathy. The second analysis included 13 patients with inflammatory cardiomyopathy who underwent immunosuppressive therapy after baseline magnetocardiography measurement. Finally, diagnostic accuracy of magnetocardiography was tested in 3 independent cohorts (total n=23) and 1 patient, who developed vaccine‐related myocarditis. First, we identified a magnetocardiography vector to differentiate between patients with cardiomyopathy versus patients without cardiomyopathy (vector of ≥0.051; sensitivity, 0.59; specificity, 0.95; positive predictive value, 93%; and negative predictive value, 64%). All patients with inflammatory cardiomyopathy, including a patient with mRNA vaccine‐related myocarditis, had a magnetocardiography vector ≥0.051. Second, we evaluated the ability of the magnetocardiography vector to reflect treatment response. We observed a decrease of the pathologic magnetocardiography vector toward normal in all 13 patients who were clinically improving under immunosuppressive therapy. Magnetocardiography detected treatment response as early as day 7, whereas echocardiographic detection of treatment response occurred after 1 month. The magnetocardiography vector decreased from 0.10 at baseline to 0.07 within 7 days (P=0.010) and to 0.03 within 30 days (P
- Published
- 2023
- Full Text
- View/download PDF
40. Prognostic Value of Right Ventricular Function in Patients With Suspected Myocarditis Undergoing Cardiac Magnetic Resonance.
- Author
-
Bernhard, Benedikt, Schnyder, Aaron, Garachemani, Davide, Fischer, Kady, Tanner, Giulin, Safarkhanlo, Yasaman, Stark, Anselm W., Schütze, Jonathan, Pavlicek-Bahlo, Maryam, Greulich, Simon, Johner, Caroline, Wahl, Andreas, Benz, Dominik C., Kwong, Raymond Y., and Gräni, Christoph
- Abstract
Risk-stratification of myocarditis is based on functional parameters and tissue characterization of the left ventricle (LV), whereas right ventricular (RV) involvement remains mostly unrecognized. In this study, the authors sought to analyze the prognostic value of RV involvement in myocarditis by cardiac magnetic resonance (CMR). Patients meeting the recommended clinical criteria for suspected myocarditis were enrolled at 2 centers. Exclusion criteria were the evidence of coronary artery disease, pulmonary artery hypertension or structural cardiomyopathy. Biventricular ejection fraction, edema according to T2-weighted images, and late gadolinium enhancement (LGE) were linked to a composite end point of major adverse cardiovascular events (MACE), including heart failure hospitalization, ventricular arrhythmia, recurrent myocarditis, and death. Among 1,125 consecutive patients, 736 (mean age: 47.8 ± 16.1 years) met the clinical diagnosis of suspected myocarditis and were followed for 3.7 years. Signs of RV involvement (abnormal right ventricular ejection fraction [RVEF], RV edema, and RV-LGE) were present in 188 (25.6%), 158 (21.5%), and 92 (12.5%) patients, respectively. MACE occurred in 122 patients (16.6%) and was univariably associated with left ventricular ejection fraction (LVEF), LV edema, LV-LGE, RV-LGE, RV edema, and RVEF. In a series of nesting multivariable Cox regression models, the addition of RVEF (HR adj : 0.974 [95% CI: 0.956-0.993]; P = 0.006) improved prognostication (chi-square test = 89.5; P = 0.001 vs model 1; P = 0.006 vs model 2) compared with model 1 including only clinical variables (chi-square test = 28.54) and model 2 based on clinical parameters, LVEF, and LV-LGE extent (chi-square test = 78.93). This study emphasizes the role of RV involvement in myocarditis and demonstrates the independent and incremental prognostic value of RVEF beyond clinical variables, CMR tissue characterization, and LV function. (Inflammatory Cardiomyopathy Bern Registry [FlamBER]; NCT04774549 ; CMR Features in Patients With Suspected Myocarditis [CMRMyo]; NCT03470571) [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
41. Hybrid-PET/MRT bei inflammatorischer Kardiomyopathie.
- Author
-
Krumm, Patrick, Greulich, Simon, la Fougère, Christian, and Nikolaou, Konstantin
- Abstract
Copyright of Die Radiologie is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2022
- Full Text
- View/download PDF
42. Diagnosis, management, and outcome of cardiac sarcoidosis and giant cell myocarditis: a Swedish single center experience
- Author
-
Emanuele Bobbio, Clara Hjalmarsson, Marie Björkenstam, Christian L. Polte, Anders Oldfors, Ulf Lindström, Pia Dahlberg, Sven-Erik Bartfay, Piotr Szamlewski, Amar Taha, Egidija Sakiniene, Kristjan Karason, Niklas Bergh, and Entela Bollano
- Subjects
Cardiac sarcoidosis ,Giant cell myocarditis ,Inflammatory cardiomyopathy ,Myocarditis ,Endomyocardial biopsy ,Heart failure ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Background Cardiac sarcoidosis (CS) and giant cell myocarditis (GCM) are rare diseases that share some similarities, but also display different clinical and histopathological features. We aimed to compare the demographics, clinical presentation, and outcome of patients diagnosed with CS or GCM. Method We compared the clinical data and outcome of all adult patients with CS (n = 71) or GCM (n = 21) diagnosed at our center between 1991 and 2020. Results The median (interquartile range) follow-up time for patients with CS and GCM was 33.5 [6.5–60.9] and 2.98 [0.6–40.9] months, respectively. In the entire cohort, heart failure (HF) was the most common presenting manifestation (31%), followed by ventricular arrhythmias (25%). At presentation, a left ventricular ejection fraction of
- Published
- 2022
- Full Text
- View/download PDF
43. Inflammatory cardiomyopathy of possibly overlapping aetiology: a case posing treatment dilemma and potential association
- Author
-
Shun Nakagama, Katherine Candray, Tasuku Yamamoto, Yuta Tsugeno, Yu Nakagama, Yasutoshi Kido, Yuko Nitahara, Yasuhiro Maejima, and Tetsuo Sasano
- Subjects
Atrioventricular block ,Inflammatory cardiomyopathy ,Sarcoidosis ,Chagas disease ,Trypanosoma cruzi ,Latin America ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract We report on a 52‐year‐old Brazilian immigrant woman with past histories of chronic kidney disease and uveitis, presenting with symptomatic atrioventricular block. Her country of origin being endemic for Trypanosoma cruzi infection, we suspected Chagas disease as the aetiology, diagnosis of which was confirmed by serological tests. Further systemic workup identified an emerging nodular lesion in the lung, which turned out to be a sarcoid epithelioid granuloma on biopsy. Involvement of the kidneys and eyes was suggestive of systemic extension of the lung sarcoidosis. Although imaging modalities did not detect inflammatory foci in the myocardium, the rare coexistence of histologically proven sarcoidosis raised the intriguing concept of cardiac manifestation having arisen from two possibly overlapping aetiologies: Chagas disease and cardiac sarcoidosis. The case highlights a treatment dilemma increasingly likely to be encountered in this globalized world, and also raises the potential, but intriguing, association of these two diseases.
- Published
- 2022
- Full Text
- View/download PDF
44. Transgenic Mice Expressing Functional TCRs Specific to Cardiac Myhc-α 334–352 on Both CD4 and CD8 T Cells Are Resistant to the Development of Myocarditis on C57BL/6 Genetic Background
- Author
-
Meghna Sur, Mahima T. Rasquinha, Rajkumar Arumugam, Chandirasegaran Massilamany, Arunkumar Gangaplara, Kiruthiga Mone, Ninaad Lasrado, Bharathi Yalaka, Aakash Doiphode, Channabasavaiah Gurumurthy, David Steffen, and Jay Reddy
- Subjects
TCR transgenic mice ,cardiac myosin-α 334–352 ,myocarditis ,inflammatory cardiomyopathy ,Cytology ,QH573-671 - Abstract
Myocarditis is a predominant cause of congestive heart failure and sudden death in children and young adolescents that can lead to dilated cardiomyopathy. Lymphocytic myocarditis mediated by T cells can result from the recognition of cardiac antigens that may involve CD4 or CD8 T cells or both. In this report, we describe the generation of T cell receptor (TCR) transgenic mice on a C57BL/6 genetic background specific to cardiac myosin heavy chain (Myhc)-α 334–352 and make the following observations: First, we verified that Myhc-α 334–352 was immunogenic in wild-type C57BL/6 mice and induced antigen-specific CD4 T cell responses despite being a poor binder of IAb; however, the immunized animals developed only mild myocarditis. Second, TCRs specific to Myhc-α 334–352 in transgenic mice were expressed in both CD4 and CD8 T cells, suggesting that the expression of epitope-specific TCR is common to both cell types. Third, although T cells from naïve transgenic mice did not respond to Myhc-α 334–352, both CD4 and CD8 T cells from animals immunized with Myhc-α 334–352 responded to the peptide, indicating that antigen priming is necessary to break tolerance. Fourth, although the transgenic T cells could produce significant amounts of interferon-γ and interleukin-17, the immunized animals developed only mild disease, indicating that other soluble factors might be necessary for developing severe myocarditis. Alternatively, the C57BL/6 genetic background might be a major contributing factor for resistance to the development of myocarditis. Taken together, our model permits the determination of the roles of both CD4 and CD8 T cells to understand the disease-resistance mechanisms of myocarditis in a single transgenic system antigen-specifically.
- Published
- 2023
- Full Text
- View/download PDF
45. A case of cardiac sarcoidosis mimicking Brugada syndrome
- Author
-
Vickram Vignesh Rangaswamy, Daljeet Kaur Saggu, Sachin Yalagudri, and Narasimhan Calambur
- Subjects
Cardiac sarcoidosis ,Ventricular fibrillation storm ,Inflammatory cardiomyopathy ,Brugada phenocopy ,Brugada syndrome ,Catheter ablation ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
A 17-year-old boy was admitted for management of ventricular fibrillation (VF) with intermittent Brugada pattern on ECG. On evaluation, cardiac MRI revealed myocardial scar and mediastinal lymphadenopathy. 18-Fluorodeoxyglucose positron emission tomography scan showed inflammation in the heart, lungs, and lymph nodes. He was diagnosed as a case of cardiac sarcoidosis (CS) and treated with steroids. However, there was a reactivation of cardiac inflammation and the development of a second VF storm. Following catheter ablation, the patient's arrhythmia improved. This report highlights the inflammation due to CS mimicking channelopathic features.
- Published
- 2022
- Full Text
- View/download PDF
46. Biomarkers for Myocarditis and Inflammatory Cardiomyopathy.
- Author
-
Suresh, Abhilash, Martens, Pieter, and Tang, W. H. Wilson
- Abstract
Purpose of Review: Myocarditis is a disease caused by inflammation of the heart that can progress to dilated cardiomyopathy, heart failure, and eventually death in many patients. Several etiologies are implicated in the development of myocarditis including autoimmune, drug-induced, infectious, and others. All causes lead to inflammation which causes damage to the myocardium followed by remodeling and fibrosis. This review aims to summarize recent findings in biomarkers for myocarditis and highlight the most promising candidates. Recent Findings: Current methods of diagnosing myocarditis, including imaging and endomyocardial biopsy, are invasive, expensive, and often not done early enough to affect progression. Research is being done to find biomarkers of myocarditis that are cost-effective, accurate, and prognostically informative. These biomarkers would allow for earlier screening for myocarditis, as well as earlier treatment, and a better understanding of the disease course for specific patients. Summary: Early diagnosis of myocarditis with biomarkers may allow for prompt treatment to improve outcomes in patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
47. Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy: 20-year follow-up of the TIMIC trial.
- Author
-
Chimenti, Cristina, Russo, Matteo Antonio, and Frustaci, Andrea
- Subjects
IMMUNOSUPPRESSIVE agents ,CARDIOMYOPATHIES ,VENTRICULAR ejection fraction ,HEART transplantation ,IMPLANTABLE cardioverter-defibrillators ,PERIPARTUM cardiomyopathy ,CHRONIC active hepatitis - Abstract
Aims Long-term results of the Tailored IMmunosuppression in virus-negative Inflammatory Cardiomyopathy (TIMIC) trial protocol have been evaluated. Methods and results Eighty-five patients with endomyocardial biopsy-proven virus-negative chronic inflammatory cardiomyopathy were enrolled in the randomized, double-blind, placebo-controlled TIMIC trial and received prednisone and azathioprine (n = 43) vs. placebo (n = 42) for 6 months. Immunosuppressive treatment promoted an improvement in cardiac function in 88% of the cases compared with none of the patients in the placebo group, which were switched to a 6-month immunosuppressive therapy at the end of the 6-month study period. Long-term (up to 20 years) clinical outcomes of the whole cohort of 85 patients originally enrolled in the TIMIC trial (Group A) were compared with those of a 1:2 propensity score-matched control cohort of patients untreated with the TIMIC protocol (Group B) and followed for a comparable period of time. The primary outcome was a composite of cardiovascular death and heart transplantation. At long-term follow-up, the risk of cardiovascular death [hazard ratio (HR) 6.77; 95% confidence interval (CI) 2.36–19.45] and heart transplantation (HR 7.92; 95% CI 1.80–34.88) was significantly higher in Group B patients. Group A showed a persistent improvement in the left ventricular ejection fraction compared with Group B (HR 7.24; 95% CI 3.05–17.18). A higher number of Group B patients underwent implantable cardioverter defibrillator implantation. The incidence of recurrent myocarditis was similar between groups, and patients with evidence of a recurrent cardiac inflammatory process promptly responded to a TIMIC protocol application. Conclusion Virus-negative inflammatory cardiomyopathy benefits from immunosuppressive therapy even after long-term follow-up. Recurrence appears to respond to a new TIMIC protocol application. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
48. Role of Endomyocardial Biopsy in Diagnostics of Myocarditis.
- Author
-
Vidusa, Liga, Kalejs, Oskars, Maca-Kaleja, Aija, and Strumfa, Ilze
- Subjects
- *
COVID-19 pandemic , *MYOCARDITIS , *BIOPSY - Abstract
Endomyocardial biopsy as the cornerstone of diagnostics has been re-evaluated throughout the years, leaving unanswered questions on the precedence of it. The reported incidence of myocarditis has increased during the pandemic of coronavirus disease 2019 (COVID-19), reinforcing discussions on appropriate diagnostics of myocarditis. By analysis of evidence-based literature published within the last demi-decade, we aimed to summarize the most recent information in order to evaluate the current role of endomyocardial biopsy in diagnostics and management of myocarditis. For the most part, research published over the last five years showed ongoing uncertainty regarding the use, informativeness, safety and necessity of performing a biopsy. Special circumstances, such as fulminant clinical course or failure to respond to empirical treatment, were reconfirmed as justified indications, with a growing applicability of non-invasive diagnostic approaches for most other cases. We concluded that endomyocardial biopsy, if performed properly and with adjunct diagnostic methods, holds a critical role for treatment correction in specific histological subtypes of myocarditis and for differential diagnosis between immune-mediated myocarditis and secondary infections due to immunosuppressive treatment. A high level of possible misdiagnosing was detected, indicating the need to review terminology used to describe findings of myocardial inflammation that did not meet Dallas criteria. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
49. Съвременни доказателства за ролята на вирусите и имунните клетки при миокардит и инфламаторна кардиомиопатия.
- Author
-
Даскалов, И. and Демиревска, Л.
- Abstract
In this review we summarize the current data about the etiopathogenesis of the virus myocarditis and inflammatory cardiomyopathy. Knowledge gaps, available experimental models and future directions are discussed. Unclear questions about the cardiovascular effects associated with COVID-19 infection are commented. This review is based on the latest published data of European, American and Japanese Heart Failure Association from 2021. [ABSTRACT FROM AUTHOR]
- Published
- 2022
50. Myocarditis Associated With Anti-IgLON5 Autoimmune Disease Following Immune Checkpoint Inhibitor Therapy.
- Author
-
Howick V JF, Singh J, Saric P, Cooper LT Jr, and Bois JP
- Abstract
Myocarditis is an inflammatory injury of the myocardium. Viral infections are the most common etiology, but less frequently, inflammatory myocardial injury can result from systemic autoimmune diseases. We present the first reported case of myocarditis in a patient with anti-IgLON5 disease., Competing Interests: The authors have reported that they have no relationships relevant to the contents of this paper to disclose., (© 2024 The Authors.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.